{
    "id": 7586,
    "fullName": "JAK2 M929I",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "JAK2 M929I is a gatekeeper mutation that lies within the protein kinase domain 2 of the Jak2 protein (PMID: 22916261, PMID: 23823659). M929I is predicted to confer a gain of function to the Jak2 protein as demonstrated by increased Jak2 and Stat5 phosphorylation (PMID: 22916261), and has also been described as a secondary drug resistance mutation in the context of other Jak2 activating mutations (PMID: 22916261, PMID: 23823659, PMID: 21926964).",
            "references": [
                {
                    "id": 3041,
                    "pubMedId": 23823659,
                    "title": "Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23823659"
                },
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                },
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3717,
        "geneSymbol": "JAK2",
        "terms": [
            "JAK2",
            "JTK10",
            "THCYT3"
        ]
    },
    "variant": "M929I",
    "createDate": "06/14/2015",
    "updateDate": "10/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 150883,
        "transcript": "NM_004972",
        "gDna": "chr9:g.5090471G>C",
        "cDna": "c.2787G>C",
        "protein": "p.M929I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21178,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 M929I double mutation were sensitive to treatment with AZD1480 in culture, demonstrating growth inhibition (PMID: 21926964).",
            "molecularProfile": {
                "id": 7535,
                "profileName": "JAK2 V617F JAK2 M929I"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21179,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 M929I double mutation were sensitive to treatment with Lestaurtinib (CEP-701) in culture, demonstrating growth inhibition (PMID: 21926964).",
            "molecularProfile": {
                "id": 7535,
                "profileName": "JAK2 V617F JAK2 M929I"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21176,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 M929I double mutation were sensitive to treatment with Momelotinib in culture, demonstrating growth inhibition (PMID: 21926964).",
            "molecularProfile": {
                "id": 7535,
                "profileName": "JAK2 V617F JAK2 M929I"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21177,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 M929I double mutation were sensitive to treatment with Inrebic (fedratinib) in culture, demonstrating growth inhibition (PMID: 21926964).",
            "molecularProfile": {
                "id": 7535,
                "profileName": "JAK2 V617F JAK2 M929I"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2426,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 M929I double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7535,
                "profileName": "JAK2 V617F JAK2 M929I"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5579,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21292,
                "profileName": "ETV6 - JAK2 JAK2 M929I"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7471,
            "profileName": "JAK2 M929I",
            "profileTreatmentApproaches": [
                {
                    "id": 5336,
                    "name": "JAK2 Inhibitor",
                    "profileName": "JAK2 M929I"
                },
                {
                    "id": 5335,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "JAK2 M929I"
                }
            ]
        },
        {
            "id": 7535,
            "profileName": "JAK2 V617F JAK2 M929I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21292,
            "profileName": "ETV6 - JAK2 JAK2 M929I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 150881,
            "transcript": "NM_001322195",
            "gDna": "chr9:g.5090471G>C",
            "cDna": "c.2787G>C",
            "protein": "p.M929I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150882,
            "transcript": "NM_001322196",
            "gDna": "chr9:g.5090471G>C",
            "cDna": "c.2787G>C",
            "protein": "p.M929I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150883,
            "transcript": "NM_004972",
            "gDna": "chr9:g.5090471G>C",
            "cDna": "c.2787G>C",
            "protein": "p.M929I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150880,
            "transcript": "NM_001322194",
            "gDna": "chr9:g.5090471G>C",
            "cDna": "c.2787G>C",
            "protein": "p.M929I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}